10-K/A: Coeptis Therapeutics Restates 2022 Financials Due to Accounting Error

Coeptis Therapeutics Holdings, Inc. has filed an amended 10-K to restate its 2022 financials due to an error in accounting for a convertible promissory note.

Summary

• Coeptis Therapeutics Holdings, Inc. is restating its 2022 financial statements due to an error in accounting for a $350,000 convertible promissory note.
• The note was issued to an unrelated third party for legal services related to the merger transaction on October 28, 2022.
• Management determined that the original 10-K did not properly account for the issuance of this note.
• The restatement affects the Consolidated Balance Sheet for the year ended December 31, 2022, specifically impacting Notes payable, current portion, and Accumulated deficit.
• The company concluded its evaluation on March 19, 2024, and determined that the errors required the filing of Amendment No. 1.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financials, which indicates an error in accounting and potential weaknesses in internal controls. This can erode investor confidence.

Negatives

• The company had to restate its financials due to an accounting error.
• The error involved a convertible promissory note, indicating potential complexities in financial transactions.
• The restatement may raise concerns about the company's internal controls.

Risks

• The restatement of financials may negatively impact investor confidence.
• The company's internal controls over financial reporting have been identified as a material weakness.
• The company has a history of losses and may not achieve or maintain profitability.
• The company needs to obtain financing to continue operations and pursue strategic transactions.
• The company operates in a highly competitive and regulated business environment.

Future Outlook

The document does not provide specific forward-looking statements beyond the need to correct the financial statements.

Management Comments

• Management determined the Original Form 10-K does not give effect to the issuance of the note payable.
• Management concluded its evaluation and determined that the identified errors required the filing of Amendment No. 1.

Industry Context

The restatement highlights the importance of accurate financial reporting, especially for companies involved in complex transactions like mergers and convertible debt issuances. It also underscores the need for robust internal controls in the biotechnology and pharmaceutical industries, where financial stability is crucial for research and development.

Comparison to Industry Standards

• Restatements due to accounting errors are not uncommon, but they can raise concerns about a company's financial controls.
• Companies like Amarin Corporation and Mallinckrodt have also had to restate financials in the past due to accounting errors.
• The specific error related to a convertible note is a common area of complexity in financial reporting, especially for companies with frequent financing activities.
• The impact of the restatement on Coeptis is relatively small in terms of dollar value, but the need to restate can still impact investor confidence.

Stakeholder Impact

• Shareholders may be concerned about the accuracy of the company's financial reporting.
• Creditors may reassess the company's creditworthiness.
• Employees may be concerned about the company's financial stability.

Next Steps

• The company needs to remediate the identified material weaknesses in its internal control over financial reporting.
• The company needs to ensure accurate accounting for all financial transactions in the future.
• The company needs to regain investor confidence following the restatement.

Key Dates

Keywords

restatement, financials, accounting error, convertible note, promissory note, internal controls, financial reporting, merger, debt, 10-K/A